Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piperacillin-tazobactam Dosing in ICU
NCT01198925Phase 4Completed
- Sponsor
- Ghent University Hospital
- Start
- Sep 2010
- Primary completion
- Nov 2012
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of piperacillin + tazobactam in bacterial infection (2 arms), sponsored by Ghent University Hospital. Primary endpoint: Pharmacokinetics of piperacillin at 6 hours. Started Sep 2010; status: completed.
02
Drugs
piperacillin + tazobactam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT01198925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01198925.